Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...5253545556575859606162...123124»
  • ||||||||||  Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P2 trial:  TILUR: Tislelizumab Plus Lenvatinib in Stage III-IV RCC (clinicaltrials.gov) -  Aug 3, 2022   
    P2,  N=20, Recruiting, 
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation. (Pubmed Central) -  Aug 3, 2022   
    The patient was initially treated with sorafenib and rapamycin, right pleurectomy and upper and middle lobectomies were attempted as the second treatment...Subsequently, the newly molecular targeting agents; regorafenib and lenvatinib, approved for recurrent hepatocellular carcinoma in Japan, were administered...Unfortunately, sepsis caused by cholangitis and liver abscess required the discontinuation of lenvatinib, and the patient died 73 months after the recurrence of hepatocellular carcinoma. Multidisciplinary treatment including lenvatinib is potentially acceptable for recurrent hepatocellular carcinoma after liver transplantation.
  • ||||||||||  Review, Journal:  Non-small-cell lung cancer: how to manage RET-positive disease. (Pubmed Central) -  Aug 2, 2022   
    In contrast, two RET-selective tyrosine kinase inhibitors (TKIs), selpercatinib and pralsetinib, demonstrated high response rates and manageable safety profiles, and have received FDA approval for the treatment of advanced RET-positive NSCLC regardless of previous lines of treatment...Genomic recharacterization at progression could help guide treatment choice or enrolment in clinical trials of specific next-generation RET inhibitors. Here, we review the biology, clinicopathological characteristics, targeted therapies and mechanisms of resistance of advanced NSCLC harbouring RET fusions to provide treatment guidance for these patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date:  PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov) -  Aug 2, 2022   
    P2,  N=36, Active, not recruiting, 
    Further investigation is warranted to investigate this combination regimen in advanced iCCA. Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
  • ||||||||||  EG-007 / Evergreen Therap
    Trial completion date, Trial initiation date, Trial primary completion date:  Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) -  Jul 29, 2022   
    P2,  N=28, Not yet recruiting, 
    Thus, this review focuses on the rationale for ICIs and their potential use for early or intermediate HCC stages. Trial completion date: Mar 2022 --> Mar 2024 | Initiation date: Dec 2021 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Mar 2024
  • ||||||||||  rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
    Trial completion date, Trial primary completion date:  Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Jul 29, 2022   
    P2b,  N=120, Recruiting, 
    Trial completion date: Mar 2022 --> Mar 2024 | Initiation date: Dec 2021 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Mar 2024 Trial completion date: Mar 2022 --> Mar 2024 | Trial primary completion date: Mar 2022 --> Mar 2024
  • ||||||||||  Mekinist (trametinib) / Novartis, Tafinlar (dabrafenib) / Novartis
    Dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2625;    
    Conclusions Dabrafenib plus trametinib showed high ORR with symptom improvement, however, majority of patients needed dose reduction in patients with BRAF V600E -mutated metastatic PTC. Additional follow-up period is needed for mature data of PFS and overall survival.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    NEOplus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2174;    
    P2
    Secondary endpoints are pathologic response which include pCR, MPR and pPR (MPR was defined as less than 10% of residual viable tumor cells. pPR was defined as less than 50% residual viable tumor cells); relapse-free survival (RFS), overall survival (OS) and safety etc. Enrollment began in Oct 2021.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Impact of treatment sequence on clinical outcomes in patients with thymic carcinoma (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2037;    
    CP was generally used as 1st line treatment, and the clinical outcomes were as beneficial to those in previous reports. Lenvatinib showed a satisfactory clinical outcome, even when reflecting on clinical practice, and S-1 and sunitinib showed moderate efficacies.
  • ||||||||||  Review, Journal:  Paradigm Shift in the Treatment Options of Hepatocellular Carcinoma. (Pubmed Central) -  Jul 28, 2022   
    In advanced HCC, lenvatinib has a comparable efficacy as sorafenib for the first-line therapy of HCC; while regorafenib, cabozantinib, and ramucirumab have been approved as second-line therapy after the failure of sorafenib...Atezolizumab plus bevacizumab is superior to sorafenib as the first-line therapy for advanced HCC...Systemic therapy may be used in the neoadjuvant, adjuvant, or even as initial therapy for intermediate-stage HCC. The paradigm shift of HCC treatment will improve patient outcomes.
  • ||||||||||  Review, Journal:  Changes in therapeutic options for hepatocellular carcinoma in Asia. (Pubmed Central) -  Jul 28, 2022   
    In a global randomized phase III trial (IMbrave 150 trial), the most effective of the latest drug designs was newly-emerged combination immunotherapy (atezolizumab plus bevacizumab), which has shown significantly prolonged overall survival compared to sorafenib, which was the first-line systemic therapy for more than a decade. Now, the treatment dynamics for HCC are undergoing a major transition due to two important changes: the replacement of viral-related HCC by metabolic-related HCC and the emergence of combination immune therapy.
  • ||||||||||  BBP-398 / BridgeBio
    Journal:  miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11. (Pubmed Central) -  Jul 28, 2022   
    Clinical cohort analysis revealed that HCC patients with high miR-6071 expression got more survival benefit from postoperative lenvatinib treatment than patients with low miR-6071 levels. In conclusion, our study demonstrated a regulation mechanism of LCSCs, a target against LSCSs, and a biomarker for postoperative lenvatinib treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Debate Your Colleague 02: Optimal Treatment of Recurrent Low Grade Endometrial Cancer (Hall 501) -  Jul 27, 2022 - Abstract #IGCS2022IGCS_339;    
    Different approaches to treatment including chemotherapy, checkpoint inhibitor therapy, and combination therapy with pembrolizumab and lenvatanib will be discussed. The role of hormonal therapies (i.e.megesterol acetate, letrozole, etc) and hormonal combination therapies in the treatment of low grade endometrial cancer will be highlighted.